Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim's Porcine Circovirus Vaccine Approved In China, The World's Top Hog Producer

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - German drug maker Boehringer Ingelheim announced its animal health division Vetmedica has received approval from China's Ministry Of Agriculture to market its pig vaccine Ingelvac CircoFLEX for Porcine Circovirus Disease (PCVD) in China

You may also be interested in...



Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth

SHANGHAI - Pfizer recently completed the divestment of its swine vaccine business in China to local company Harbin Bio-Vaccine, an animal health subsidiary of Harbin Pharmaceutical Group

Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth

SHANGHAI - Pfizer recently completed the divestment of its swine vaccine business in China to local company Harbin Bio-Vaccine, an animal health subsidiary of Harbin Pharmaceutical Group

Sanofi Diversifies In China With $70 Million To Expand Production Capability For Animal Health Division Merial

SHANGHAI - Sanofi-Aventis' animal health division Merial Animal Health broke ground on a $70 million expansion of its Nanchang manufacturing site, six months after Sanofi CEO Chris Viehbacher said his company aims to diversify in China

Related Content

UsernamePublicRestriction

Register

SC073080

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel